AUTL
Autolus Therapeutics Plc
A London-based biotech that engineers living immune cells called CAR-T cells into "living drugs" to fight blood cancers. Its lead therapy, marketed as Aucatzyl, treats adults with a hard-to-treat form of acute lymphoblastic leukemia. The company spun out of University College London in 2011, and its name comes from the Greek word "autos" ("self"), reflecting how it reprograms a patient's own cells to attack their cancer.
ADRUnderlying: AUTLCUSIP: 05280R100HealthcareGB1 holder
American Depositary Receipts (Sponsored ADR)
Total Value
$1.46M
Total Shares
54.4K
Net Share Change
+54.4K
Activity
1 buying
Investor
Value
Shares
Weight
Change
